Aslan Pharmaceuticals Licenses Regional Rights to BMS’ Early-Stage Cancer Drug
By Heather Cartwright
Pharma Deals Review: Vol 2011 Issue 11 (Table of Contents)
Published: 28 Nov-2011
DOI: 10.3833/pdr.v2011.i11.1616 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
As part of its Oyster strategy to advance non-core, early-stage assets, Bristol-Myers Squibb (BMS) has out-licensed regional rights to its investigational oncology compound BMS-777607 to Aslan Pharmaceuticals...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS